Royalty Report: Drugs, Cancer, Disease – Collection: 101938


Curated Royalty Rate Report
Category: Technology Licenses, Created On: 2022-04-28, Record Count: 4


This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 4

Primary Industries

  • Drugs
  • Cancer
  • Disease
  • Therapeutic
  • Pharmaceuticals
  • cardiac
  • recombinant proteins

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 101938

License Grant
A wholly-owned subsidiary of the parent company entered into a Collaboration, License and Option Agreement with Licensee to discover, develop and commercialize small molecule antagonists for immuno-oncology and precision oncology targets.
License Property
Under the Collaboration Agreement, Licensor has the responsibility for conducting all discovery and preclinical activities, including Investigational New Drug (IND) enabling studies and providing Phase 1 clinical trial supply, and Licensee is responsible for all clinical development, regulatory and commercialization efforts worldwide, excluding India and Russia. The Collaboration Agreement provides that the parties will collaborate exclusively in immuno-oncology for an initial period of approximately two years, with the option for Licensee to extend the broad immuno-oncology exclusivity.
Field of Use
This agreement pertains to the drug industry.

IPSCIO Record ID: 1249

License Grant
The Licensor entered into a worldwide collaboration with the Licensee pursuant to which the parties will each grant the other certain intellectual property Licenses and product rights on a worldwide basis in order to enable the two companies to collaborate in the discovery, development and commercialization of novel targeted therapies for the treatment of cancer.
License Property
Under the terms of the collaboration, the Licensor is responsible for discovery and preclinical development of small molecule drug candidates directed against mutually selected targets. The Licensee will have the right to select up to three Investigational New Drug candidates from six future Licensor compounds. Once selected, Licensee will be the lead party for the further development and commercialization of the selected IND candidates.
Field of Use
The rights granted apply to the healthcare industry.

IPSCIO Record ID: 255044

License Grant
The Licensor and the Licensee entered into a new Strategic Drug Development Collaboration and License Agreement, to discover, develop and commercialize potential mRNA medicines for the treatment of a range of cancers.  The Licensee has sole and exclusive responsibility for all ex-U.S. commercialization efforts.
License Property
The Licensor is responsible for conducting and funding all discovery and preclinical development activities in accordance with an agreed upon discovery program plan for the IL12 program and any other discovery program the parties agree to conduct under Agreement.
Field of Use
To work together on an immuno-oncology program focused on the intratumoral delivery of a potential mRNA medicine to make the IL12 protein.

Potential therapeutic mRNA medicines is directed at certain targets for the treatment of cardiovascular and cardiometabolic diseases and cancer, and agreed to provide related services.

IPSCIO Record ID: 213259

License Grant
Licensee has the option to obtain from the Company the full worldwide development and commercial rights to AST-005, an option to obtain three additional collaboration targets and a further option to obtain from the company the full worldwide development and commercial rights to any therapeutic candidates developed targeting the three additional collaboration targets. Additionally, Licensee has rights of first offer to some potential collaboration targets. These rights of first offer are subject to limitations in time and scope.
License Property
AST-005 is a therapeutic candidate for gene regulatory and immuno-oncology therapeutics based on the companys proprietary Spherical Nucleic Acid, or SNA, technology. The Company believe the design of Company SNAs gives rise to distinct chemical and biological properties that may provide advantages over other nucleic acid therapeutics and enable therapeutic activity outside of the liver.

The Company is conducting, on behalf of Licensee, a Phase 1b clinical trial in psoriasis patients in Germany to evaluate the effect of higher concentrations of AST-005 gel on TNF mRNA and downstream mRNA expression. We expect the results from this clinical trial to be available in late 2017.

Field of Use
This agreement pertains to the drug industry relating to developing gene regulatory and immuno-oncology therapeutics.
Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.